Narek A Tmoyan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4127988/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk. Atherothrombosis, 2022, 11, 56-75.	0.3	0
2	The relationship between the level of LÑ€(а) and the prevalence of atherosclerosis among young patients. Terapevticheskii Arkhiv, 2022, 94, 479-484.	0.8	1
3	Association of various lipid parameters with premature coronary artery disease in men. Russian Journal of Cardiology, 2022, 27, 5058.	1.4	3
4	Prevalence of familial hypercholesterolemia and hyperlipoproteinemia(a) in patients with premature acute coronary syndrome. Russian Journal of Cardiology, 2022, 27, 5041.	1.4	2
5	Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease. Journal of Cardiovascular Development and Disease, 2021, 8, 11.	1.6	12
6	Lipoprotein(a) and Cardiovascular Outcomes after Revascularization of Carotid and Lower Limbs Arteries. Biomolecules, 2021, 11, 257.	4.0	6
7	Role of inflammation, autotaxin and lipoprotein (a) in degenerative aortic valve stenosis in patients with coronary artery disease. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2598.	1.4	2
8	Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (RENESSANS). Russian Journal of Cardiology, 2019, , 7-13.	1.4	21
9	High lipoprotein(A) level is a predictor of severe carotid atherosclerosis and ischemic stroke. Atherosclerosis, 2018, 275, e159.	0.8	0
10	P5396Elevated lipoprotein(a) as a predictor of peripheral artery diseases. European Heart Journal, 2018, 39, .	2.2	0
11	Lipoprotein(a), apolipoprotein(a) phenotypes and multisite atherosclerosis. Atherosclerosis, 2018, 275, e159.	0.8	0
12	The role of lipoprotein(a) and apolipoprotein(a) phenotypes in severe atherosclerosis of coronary, carotid and lower limbs arteries. Atherosclerosis, 2018, 275, e162.	0.8	0
13	Elevated autotaxin plasma level as a marker of aortic valve stenosis in patients with coronary heart disease. Atherosclerosis, 2018, 275, e164.	0.8	0
14	High Lipoprotein(a) Level is a Predictor of Peripheral Artery Disease Regardless of the Presence of Type 2 Diabetes. Atherosclerosis Supplements, 2018, 32, 42.	1.2	0
15	The association of lipoprotein(a) and apolipoprotein(a) phenotypes with peripheral artery disease. Terapevticheskii Arkhiv, 2018, 90, 31-36.	0.8	8
16	The Role of Lipoprotein(a) in the Development of Peripheral and Carotid Atherosclerosis. Kardiologiya, 2018, 17, 70-78.	0.7	2
17	RAISED LEVEL OF LIPOPROTEIDE(A) AS A PREDICTOR OF CARDIOVASCULAR COMPLICATION POST REVASCULARIZATION OF THE LOWER EXTREMETIES ARTERIES. Russian Journal of Cardiology, 2018, , 7-12.	1.4	0
18	Inflammation markers in coronary heart disease patients with aortic valve stenosis. Russian Journal of Cardiology, 2018, , 17-22.	1.4	1

#	Article	IF	CITATIONS
19	Lipoprotein(A) level as a discriminator of severe peripheral atherosclerosis. Atherosclerosis, 2017, 263, e65-e66.	0.8	1
20	P1411Lipoprotein(a) is a marker of peripheral artery disease in the absence of coronary heart disease. European Heart Journal, 2017, 38, .	2.2	1